XNYS · Medical Devices
Last stored close · Sep 18, 2026
Close · Sep 18, 2026
$95.36+1.18%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
59/100
Positive
Score components
TickerWhale View
Zimmer Biomet Holdings scores 59 out of 100 overall, which we rate positive. Valuation is its strongest area and Risk its weakest.
What helps
- Technical
- Valuation
- Sentiment Signal
What to watch
- Quality & growth
- Risk
Quality & growth
30%44Weak
- Revenue growth 8.6%
- EPS growth 0.0%
Valuation
25%85Strong
- P/E 22.8
- EV/Sales 3.0
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
#489 by market cap in our coverage · ~17,000 employees · Listed 2001-08-07 · www.zimmerbiomet.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#56 / 139sector rank by TickerWhale Score
TickerWhale Score 59 vs sector average 55.1 (+3.9)
Revenue growth (industry)Top 61%
Gross margin (industry)Top 28%
Return on equity (industry)Top 78%
P/E (industry)Cheaper than 80%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
67/100Positive vs universe
Ranks 67th of 100 covered names on our technical composite — the composite itself scores 56/100 · 25% of the TickerWhale Score
Classic chart indicators
Strong Sell
0 buy · 4 sell · 4 neutral of 8 votes
TickerWhale rates ZBH's technical setup middling — 67th percentile of the covered universe. Classic chart indicators lean sell — they read this stock on its own over days, where our score ranks it against every covered name over months, so the two often part company.
Moving averages
3 / 9constructive
- vs 200-day+4.3%
- vs 50-day-0.8%
Momentum
Mixed
- RSI (14)47 · neutral
- Stochasticsell
- CCIneutral
- Williams %Rneutral
Trend
Mixed
- ADX (14) trend strength18· weak trend
- MACD (12,26,9)sell(histogram -0.445)
How the classic verdict is reached
Moving averages (9) agree on sell — 3 buy vs 4 sell — and carry one vote between them.
Oscillators (7) vote individually: 0 buy · 3 sell · 4 neutral.
Result — 0 buy vs 4 sell of 8 votes = Strong Sell. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-09-18 · revised_latestValuation multiples
- P/E (TTM)22.8
- P/S (TTM)2.2
- P/B1.5
- EV/EBITDA—
- EV/Sales3.0
- PEG—
Profitability & returns
- Gross margin69.9%
- Net margin9.5%
- ROE6.4%
- Debt/Equity0.59
Growth
- Revenue growth (YoY)8.6%
- EPS growth (YoY)0.0%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $18.4B
Fundamentals history
Reported statement totals across recent periods.
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: MU →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ZBHCurrentZimmer Biomet Holdings | 59 | 56 | 22.8 | — | 1.5 | 3.0 | $95.36 | +1.18% | +8.6% | ||
| EXELExelixis | 81 | 80 | 17.6 | — | 8.2 | 6.1 | $58.36 | -0.22% | +9.2% | ||
| INCYIncyte | 81 | 76 | 16.2 | — | 4.1 | 3.8 | $125.31 | -1.81% | +26.9% | ||
| ACADAcadia Pharmaceuticals | 80 | 63 | 12.4 | — | 3.6 | 3.8 | $27.29 | -0.58% | +11.8% | ||
| OSCROscar Health Inc - | 78 | 67 | 19.5 | — | 5.2 | 0.5 | $32.13 | +0.47% | +43.1% | ||
| TGTXTG Therapeutics | 77 | 73 | 20.3 | — | 14.8 | 11.5 | $56.87 | +0.71% | +76.1% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.